Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Genetically Engineered Mouse Models That Closely Resemble Human Patients Enable More Relevant Cancer Drug Studies

By BiotechDaily International staff writers
Posted on 18 Jul 2013
Image: Ultrasound imaging of mouse tumor showing response to chemotherapy. The mouse model allowed researchers to derive a new biomarker of chemotherapy responsiveness (Photo courtesy of Perou Laboratory at the University of North Carolina).
Image: Ultrasound imaging of mouse tumor showing response to chemotherapy. The mouse model allowed researchers to derive a new biomarker of chemotherapy responsiveness (Photo courtesy of Perou Laboratory at the University of North Carolina).
The use of genetically engineered mouse models (GEMMs) as recipients for xenografts of various types of human tumors enables study of tumor growth in an animal system with intact immune system and identification of genetic signatures that can be used to predict the responsiveness of these tumors to drug treatment.

Investigators at the University of North Carolina (Chapel Hill, USA) reasoned that drug studies conducted using traditional mouse models, which lack functional immune systems, could produce misleading results. To evaluate this theory they examined the efficacy of four chemotherapeutic or targeted anticancer drugs, alone and in combination, using mouse models representing three distinct breast cancer subtypes: Basal-like (GEMM), Luminal B (GEMM), and Claudin-low (non-GEMM). Drugs tested as single agents included carboplatin, paclitaxel, erlotinib, and lapatinib. The investigators used RNA expression analysis to profile tumors in order to develop signatures that corresponded to treatment and response and then tested their predictive potential using human patient data.

Results published in the June 18, 2013, online edition of the journal Clinical Cancer Research revealed that while lapatinib alone exhibited exceptional efficacy in one model system, generally single-agent activity was modest, while some combination therapies were more active and life prolonging. Through analysis of RNA expression in this large set of chemotherapy-treated mouse tumors, a pair of gene expression signatures was identified that predicted pathological complete response to neoadjuvant anthracycline/taxane (doxorubicin/paclitaxel) therapy in human patients with breast cancer.

Results presented in this study showed that mouse-derived gene signatures could predict drug response even after accounting for common clinical variables and other predictive genomic signatures, suggesting that mice could be used to identify new biomarkers for human cancer patients. Senior author Dr. Charles Perou, professor of molecular oncology research at the University of North Carolina, said, “This is a wonderful example of how well chosen mouse models can inform a human disease state. In this case we used years of research to match the models to specific human subtypes, and then treated the animals with therapies identical to what human cancer patients are receiving. We were ultimately able to develop a biomarker of treatment response from the mouse that works in humans.”

Related Links:
University of North Carolina



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.